SOHO 2023 | Efficacy outcomes of patients with myeloma who achieved sustained MRD negativity in CARTITUDE-1
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses results from the CARTITUDE-1 study (NCT03548207), focusing on the observation of stringent complete responses (sCR) in patients with heavily pre-treated relapsed/refractory (R/R) multiple myeloma who demonstrated sustained measurable residual disease (MRD) negativity following treatment with ciltacabtagene autoleucel (cilta-cel). Dr Lin also shares that bone marrow MRD status could not be predicted from the baseline characteristics of patients, highlighting the importance of finding the best approach to monitor patients after CAR-T therapy. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Bluebird Bio: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Legend: Consultancy; Juno: Consultancy; Celgene: Consultancy, Research Funding; Novartis: Consultancy; Kite, a Gilead Company: Consultancy, Research Funding; Gamida Cell: Consultancy; Takeda: Research Funding; Vineti: Consultancy; Sorrento: Consultancy; Merck: Research Funding.
